ALSO READ| Alert! Delhi-NCR's Air Quality Heading Towards 'Emergency' Level
Recently Pfizer Inc and German biotech company BioNTech BNT162b2, announced that their mRNA-based vaccine has demonstrated evidence of efficacy against COVID-19 in participants. This came after the first interim efficacy analysis conducted on November 8, 2020, by an external, independent Data Monitoring Committee (DMC) from the Phase 3 clinical study.
"Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis," Pfizer said in a statement.
The US government has also said that if Pfizer is able to submit positive initial data from its vaccine trials, then it will start vaccination in America from December. Health Secretary Alex Azar said in a report by Reuters that after FDA authorization, the US will receive about 20 million doses of the Pfizer vaccine per month.
The report also said that Covid 19 vaccination will begin with the elderly in nursing homes and assisted living facilities, healthcare workers, and first responders. The goal is to complete these by end of January.